S&P 500   4,272.62 (-0.36%)
DOW   33,316.43 (-0.57%)
QQQ   362.09 (+1.07%)
AAPL   174.09 (+1.68%)
MSFT   320.61 (+1.54%)
META   305.67 (+1.82%)
GOOGL   133.85 (+2.28%)
AMZN   129.67 (+2.01%)
TSLA   253.38 (+1.26%)
NVDA   450.62 (+3.59%)
NIO   8.83 (-2.32%)
BABA   86.51 (-0.27%)
AMD   102.91 (+0.09%)
T   14.86 (-1.07%)
F   12.35 (-0.56%)
MU   67.67 (-0.53%)
CGC   0.78 (-0.36%)
GE   109.30 (-1.13%)
DIS   81.08 (+0.04%)
AMC   7.94 (-0.63%)
PFE   33.51 (+1.03%)
PYPL   58.66 (+0.34%)
NFLX   383.45 (+1.55%)
S&P 500   4,272.62 (-0.36%)
DOW   33,316.43 (-0.57%)
QQQ   362.09 (+1.07%)
AAPL   174.09 (+1.68%)
MSFT   320.61 (+1.54%)
META   305.67 (+1.82%)
GOOGL   133.85 (+2.28%)
AMZN   129.67 (+2.01%)
TSLA   253.38 (+1.26%)
NVDA   450.62 (+3.59%)
NIO   8.83 (-2.32%)
BABA   86.51 (-0.27%)
AMD   102.91 (+0.09%)
T   14.86 (-1.07%)
F   12.35 (-0.56%)
MU   67.67 (-0.53%)
CGC   0.78 (-0.36%)
GE   109.30 (-1.13%)
DIS   81.08 (+0.04%)
AMC   7.94 (-0.63%)
PFE   33.51 (+1.03%)
PYPL   58.66 (+0.34%)
NFLX   383.45 (+1.55%)
S&P 500   4,272.62 (-0.36%)
DOW   33,316.43 (-0.57%)
QQQ   362.09 (+1.07%)
AAPL   174.09 (+1.68%)
MSFT   320.61 (+1.54%)
META   305.67 (+1.82%)
GOOGL   133.85 (+2.28%)
AMZN   129.67 (+2.01%)
TSLA   253.38 (+1.26%)
NVDA   450.62 (+3.59%)
NIO   8.83 (-2.32%)
BABA   86.51 (-0.27%)
AMD   102.91 (+0.09%)
T   14.86 (-1.07%)
F   12.35 (-0.56%)
MU   67.67 (-0.53%)
CGC   0.78 (-0.36%)
GE   109.30 (-1.13%)
DIS   81.08 (+0.04%)
AMC   7.94 (-0.63%)
PFE   33.51 (+1.03%)
PYPL   58.66 (+0.34%)
NFLX   383.45 (+1.55%)
S&P 500   4,272.62 (-0.36%)
DOW   33,316.43 (-0.57%)
QQQ   362.09 (+1.07%)
AAPL   174.09 (+1.68%)
MSFT   320.61 (+1.54%)
META   305.67 (+1.82%)
GOOGL   133.85 (+2.28%)
AMZN   129.67 (+2.01%)
TSLA   253.38 (+1.26%)
NVDA   450.62 (+3.59%)
NIO   8.83 (-2.32%)
BABA   86.51 (-0.27%)
AMD   102.91 (+0.09%)
T   14.86 (-1.07%)
F   12.35 (-0.56%)
MU   67.67 (-0.53%)
CGC   0.78 (-0.36%)
GE   109.30 (-1.13%)
DIS   81.08 (+0.04%)
AMC   7.94 (-0.63%)
PFE   33.51 (+1.03%)
PYPL   58.66 (+0.34%)
NFLX   383.45 (+1.55%)
NASDAQ:PHAR

Pharming Group (PHAR) Stock Forecast, Price & News

$12.40
+1.00 (+8.77%)
(As of 11:01 AM ET)
Compare
Today's Range
$12.39
$12.56
50-Day Range
$11.40
$15.10
52-Week Range
$8.65
$17.81
Volume
1,499 shs
Average Volume
12,153 shs
Market Capitalization
$813.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.50

Pharming Group MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
210.5% Upside
$38.50 Price Target
Short Interest
Healthy
0.00% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.59mentions of Pharming Group in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.36) to ($0.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

701st out of 969 stocks

Pharmaceutical Preparations Industry

333rd out of 453 stocks


PHAR stock logo

About Pharming Group (NASDAQ:PHAR) Stock

Pharming Group N.V. is a Dutch biotech company specializing in developing innovative therapies for rare diseases. The company aims to improve patients' lives suffering from debilitating illnesses by developing and commercializing safe and effective treatments.

Pharming's lead product is Ruconest, a recombinant human C1 esterase inhibitor indicated for the treatment of hereditary angioedema (HAE) attacks. HAE is a rare and life-threatening genetic disorder that causes swelling in various body parts, including the hands, feet, face, and airways. Ruconest is the only recombinant C1 inhibitor approved by the FDA and EMA for the treatment of acute attacks of HAE in adults and adolescents.

The company's target market is patients suffering from HAE, which is estimated to affect approximately 1 in 10,000 to 1 in 50,000 people worldwide. The key customers for Ruconest are hospitals, clinics, and specialized treatment centers that provide care for patients with HAE.

Pharming is headquartered in Leiden, Netherlands, with additional offices in the United States and Switzerland. The company was founded in 1986 and went public on Euronext Amsterdam in 1999. In 2019, the company established a US subsidiary and started trading on the NASDAQ Global Market.

Pharming has achieved several key milestones in recent years. In 2019, the FDA approved Ruconest for treating acute attacks of HAE in pediatric patients, expanding the drug's market potential. In 2020, the company received a $10 million milestone payment from its partner, Kyowa Kirin, for the achievement of a sales target for Ruconest in Japan.

Sijmen de Vries is the Chief Executive Officer of Pharming and has been with the company since 2009. He has over 30 years of experience in the pharmaceutical industry, including leadership positions at Genzyme, AstraZeneca, and Schering-Plough.

Pharming reported revenue gradually increasing yearly over the past several years. The company's gross profit margin is around 80%, reflecting the high profitability of its products. Pharming has a manageable debt load with plenty of assets to cover liabilities. 

The company's revenue growth can be attributed to the strong performance of Ruconest, which generated sales of over $150 million a year for the past several years. The company also saw growth in its pipeline of products, with its new recombinant factor VIII product, RUCONEST® (human C1 esterase inhibitor) for treating acute HAE, receiving marketing authorization from the European Commission in 2021.

Pharming's valuation metrics are generally in line with its peers in the biotech industry. The company's price-to-earnings ratio is higher than the industry average. The company's price-to-book ratio is also higher than the industry average. These and other valuation metrics could mean investors see the stock as overvalued. 

The rare disease market is growing and lucrative, with an estimated 400 million worldwide suffering from rare diseases. The market for HAE treatments is expected to reach $2.7 billion by 2025, driven by the increasing prevalence of the disease and the introduction of new therapies.

Pharming faces competition from other biotech companies developing therapies for HAE, such as Takeda Pharmaceutical Company Limited and CSL Behring. However, Ruconest has demonstrated superior safety and efficacy compared to other C1 esterase inhibitors in clinical trials, giving the company a competitive advantage.

Pharming's pipeline includes promising products, such as RUCONEST® for treating acute HAE and Leniolisib for treating PIK3CA-related overgrowth spectrum (PROS). The company is also exploring new indications for Ruconest, such as treating pre-eclampsia and COVID-19.

Pharming has also recently announced plans to expand its manufacturing capacity with a new facility in the Netherlands. The new facility is expected to increase its production capacity and reduce reliance on third-party manufacturers, improving its gross margins and overall profitability.

The biotech industry is subject to regulatory and clinical risks, as the approval and commercialization of new products are dependent on regulatory agencies' decisions and successful clinical trials. Changes in reimbursement policies or the introduction of competing therapies could also impact the company's revenue growth.

Pharming also depends on the success of Ruconest, as it represents the majority of the company's revenue. Any unexpected safety concerns or competitive pressures could significantly impact the company's financial performance.

PHAR Price History

PHAR Stock News Headlines

Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume
RBC Capital Reaffirms Their Buy Rating on Pharming Group (PHGUF)
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
PHAR - Pharming Group N.V.
Pharming announces sale of priority review voucher
Hereditary Angioedema Market Size by 2030
See More Headlines
Receive PHAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter.

PHAR Company Calendar

Last Earnings
8/03/2023
Today
10/02/2023
Next Earnings (Estimated)
10/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PHAR
Fax
N/A
Employees
332
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$38.50
High Stock Price Forecast
$40.00
Low Stock Price Forecast
$37.00
Forecasted Upside/Downside
+208.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$13.67 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$205.62 million
Cash Flow
$0.26 per share
Book Value
$3.12 per share

Miscellaneous

Free Float
64,276,000
Market Cap
$819.84 million
Optionable
Not Optionable
Beta
0.28
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Sijmen de Vries M.B.A. (Age 64)
    M.D., MBA, Pres, CEO & Exec. Director
    Comp: $1.18M
  • Mr. Jeroen Wakkerman (Age 54)
    Chief Financial Officer
  • Ms. Mireille Sanders M.Sc. (Age 55)
    Chief Operations Officer
  • Susanne Embleton
    Investor Relations Mang.
  • Mr. Ruud Van Outersterp (Age 59)
    Chief Ethics & Compliance Officer
  • Dr. Anurag Relan M.D. (Age 51)
    MPH, Chief Medical Officer
  • Mr. Stephen Toor (Age 52)
    Chief Commercial Officer & GM Americas
  • Dr. Alexander Breidenbach M.B.A.
    Chief Bus. Officer
  • Dr. Bruno M. L. Giannetti (Age 71)
    Consultant













PHAR Stock - Frequently Asked Questions

Should I buy or sell Pharming Group stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pharming Group in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PHAR shares.
View PHAR analyst ratings
or view top-rated stocks.

What is Pharming Group's stock price forecast for 2023?

3 equities research analysts have issued 12 month target prices for Pharming Group's shares. Their PHAR share price forecasts range from $37.00 to $40.00. On average, they expect the company's stock price to reach $38.50 in the next year. This suggests a possible upside of 208.2% from the stock's current price.
View analysts price targets for PHAR
or view top-rated stocks among Wall Street analysts.

How have PHAR shares performed in 2023?

Pharming Group's stock was trading at $11.03 on January 1st, 2023. Since then, PHAR shares have increased by 13.2% and is now trading at $12.49.
View the best growth stocks for 2023 here
.

When is Pharming Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our PHAR earnings forecast
.

How were Pharming Group's earnings last quarter?

Pharming Group (NASDAQ:PHAR) announced its earnings results on Thursday, August, 3rd. The company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.04. The company had revenue of $54.90 million for the quarter, compared to analyst estimates of $51.80 million. Pharming Group had a negative trailing twelve-month return on equity of 7.57% and a negative net margin of 7.96%.

What is Pharming Group's stock symbol?

Pharming Group trades on the NASDAQ under the ticker symbol "PHAR."

How do I buy shares of Pharming Group?

Shares of PHAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pharming Group's stock price today?

One share of PHAR stock can currently be purchased for approximately $12.49.

How much money does Pharming Group make?

Pharming Group (NASDAQ:PHAR) has a market capitalization of $819.84 million and generates $205.62 million in revenue each year. The company earns $13.67 million in net income (profit) each year or ($0.23) on an earnings per share basis.

How many employees does Pharming Group have?

The company employs 332 workers across the globe.

How can I contact Pharming Group?

Pharming Group's mailing address is DARWINWEG 24, LEIDEN P7, 2333 CR. The official website for the company is www.pharming.com. The company can be reached via phone at 31-71-524-7400 or via email at investor@pharming.com.

This page (NASDAQ:PHAR) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -